Vaccines Targeting PCSK9: A Promising Alternative to Passive Immunization with Monoclonal Antibodies in the Management of Hyperlipidaemia?
- 178 Downloads
Hypercholesterolaemia is frequently observed in patients with cardiovascular diseases (CVD) and is associated with increased mortality. Statin treatment has been the standard of care for reducing low-density lipoprotein cholesterol (LDL-C) to improve cardiovascular outcomes. However, statins have limited effects in some patients and may be discontinued due to adverse effects resulting in LDL-C above target levels. The proprotein convertase subtilisin kexin type 9 (PCSK9) is a pivotal regulator in the LDL-C metabolism by degrading the LDL-C receptor on hepatocytes. Inhibition of PCSK9 by monoclonal antibodies (mAb) significantly lowers LDL-C levels and is considered to reduce the likelihood of adverse cardiac events. However, such treatment regimens are not cost-effective, and require frequent administrations at high doses that may be associated with side effects and poor drug adherence. Furthermore, it has been shown that these PCSK9 medicines may trigger the formation of antidrug antibodies followed by a significant attenuation of the LDL-C-lowering effect. Active vaccination inducing high-affinity antibodies against PCSK9 with less frequent administration intervals may be a novel promising therapeutic approach to overcome the drawback of passive immunization with PCSK9 mAb. However there is a paucity of available clinical safety and efficacy data. This article discusses challenges in the development of PCSK9 vaccines and their potential therapeutic benefits by reviewing clinical studies that evaluated the safety and efficacy of PCSK9 mAb.
Compliance with ethical standards
No external funding was used in the preparation of this manuscript.
Conflict of interest
Stefan Weisshaar and Markus Zeitlinger declare that they have no conflicts of interest that might be relevant to the contents of this manuscript.
- 2.Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383–9.Google Scholar
- 4.Athyros VG, Papageorgiou AA, Mercouris BR, et al. Treatment with atorvastatin to the National Cholesterol Educational Program goal versus ‘usual’ care in secondary coronary heart disease prevention. The GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study. Curr Med Res Opin. 2002;18:220–8.CrossRefPubMedGoogle Scholar
- 6.Jacobson TA, Maki KC, Orringer CE, et al. National lipid association recommendations for patient—centered management of dyslipidemia: part 2. J Clin Lipidol. 2015;9(S1–122):e121.Google Scholar
- 30.Food and Drug Administration. Praluent Alirocumab. 2015.https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/125559Orig1s000TOC.cfm. Accessed 18 Jan 2018.
- 31.European Medicines Agency. Praluent Alirocumab. 2015. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/003882/human_med_001915.jsp&mid=WC0b01ac058001d124. Accessed 18 Jan 2018.
- 32.Food and Drug Administration. Repatha Evolocumab. 2015. https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/125522s000lbl.pdf. Accessed 18 Jan 2018.
- 33.European Medicines Agency. Repatha Alirocumab. 2015. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/003766/human_med_001890.jsp&mid=WC0b01ac058001d124. Accessed 18 Jan 2018.
- 34.Pfizer. Pfizer discontinues global development of bococizumab, its investigational PCSK9 inhibitor. 2016. http://www.pfizer.com/news/press-release/press-release-detail/pfizer_discontinues_global_development_of_bococizumab_its_investigational_pcsk9_inhibitor. Accessed 14 Dec 2017.
- 37.Ridker PM, Amarenco P, Brunell R, et al. Evaluating bococizumab, a monoclonal antibody to PCSK9, on lipid levels and clinical events in broad patient groups with and without prior cardiovascular events: Rationale and design of the Studies of PCSK9 Inhibition and the Reduction of vascular Events (SPIRE) Lipid Lowering and SPIRE Cardiovascular Outcomes Trials. Am Heart J. 2016;178:135–44.CrossRefPubMedGoogle Scholar
- 44.Sanofi. Praluent® (alirocumab) significantly reduced risk of cardiovascular events in high-risk patients, and was associated with lower death rate 2018. http://mediaroom.sanofi.com/praluent-alirocumab-significantly-reduced-risk-of-cardiovascular-events-in-high-risk-patients-and-was-associated-with-lower-death-rate/. Accessed 29 Mar 2018.
- 45.European Medicines Agency. Product information—Repatha. 2015. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/003766/WC500191398.pdf. Accessed 18 Jan 2018.
- 49.Giugliano RP, Desai NR, Kohli P, et al. Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebo-controlled, dose-ranging, phase 2 study. Lancet. 2012;380:2007–17.CrossRefPubMedPubMedCentralGoogle Scholar
- 50.Koren MJ, Scott R, Kim JB, et al. Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 as monotherapy in patients with hypercholesterolaemia (MENDEL): a randomised, double-blind, placebo-controlled, phase 2 study. Lancet. 2012;380:1995–2006.CrossRefPubMedGoogle Scholar
- 51.Raal F, Scott R, Somaratne R, et al. Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the Reduction of LDL-C with PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder (RUTHERFORD) randomized trial. Circulation. 2012;126:2408–17.CrossRefPubMedGoogle Scholar
- 60.Koren MJ, Sabatine MS, Giugliano RP, et al. Long-term Low-Density Lipoprotein Cholesterol-Lowering Efficacy, Persistence, and Safety of Evolocumab in Treatment of Hypercholesterolemia: Results Up to 4 Years From the Open-Label OSLER-1 Extension Study. JAMA Cardiol. 2017;2:598–607.CrossRefPubMedPubMedCentralGoogle Scholar
- 61.Toth PP, Worthy G, Gandra SR, et al. Systematic review and network meta-analysis on the efficacy of evolocumab and other therapies for the management of lipid levels in hyperlipidemia. J Am Heart Assoc 2017;6(10). https://doi.org/10.1161/JAHA.116.005367.
- 65.Gumbiner B, Joh T, Liang H, et al. The effects of single- and multiple-dose administration of bococizumab (RN316/PF-04950615), a humanized IgG2Deltaa monoclonal antibody binding proprotein convertase subtilisin/kexin type 9, in hypercholesterolemic subjects treated with and without atorvastatin: Results from four phase I studies. Cardiovasc Ther. 2018. https://doi.org/10.1111/1755-5922.12309.CrossRefPubMedGoogle Scholar
- 66.Ballantyne CM, Neutel J, Cropp A, et al. Results of bococizumab, a monoclonal antibody against proprotein convertase subtilisin/kexin type 9, from a randomized, placebo-controlled, dose-ranging study in statin-treated subjects with hypercholesterolemia. Am J Cardiol. 2015;115:1212–21.CrossRefPubMedGoogle Scholar
- 72.Anderson JL, Heidenreich PA, Barnett PG, et al. ACC/AHA statement on cost/value methodology in clinical practice guidelines and performance measures: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures and Task Force on Practice Guidelines. J Am Coll Cardiol. 2014;63:2304–22.CrossRefPubMedGoogle Scholar